Buy Glaxosmithkline Consumer Healthcare; target of Rs 5950: Axis Direct

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Axis Direct's research report on Glaxosmithkline Consumer Healthcare

Net sales, EBITDA and Adj PAT grew 2%, 2% and 8% (vs. consensus expectation of 2%, -4% and -4%). Domestic sales grew 2% aided by 2.7% price hike. OPM contracted 10 bps YoY (at 20.8%), as impact of lower employee costs (-403 bps YoY) was absorbed by higher raw material costs (+229 bps YoY) and A&P spend (+146 bps YoY).

Outlook

After maintaining a neutral to negative stance for four years, we upgrade GSKCH to BUY with TP of Rs 5,950 (earlier Rs 5,300) based on fwd. P/E of 29x.Strong pricing power, category leadership and attractive valuation (26x P/E for FY19E) is a reality and improvement in the core category volume growth a strong possibility given multiple initiatives taken by the management.

For all recommendations, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More